Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00165
2008-07-11
Prospective
NIL
Joint Shantou International Eye Center, Shantou, Guangdong Province, China
Professor Nathan Congdon, Department of Ophthalmology and Visual Science
Professor Zhang Mingzhi, Director of Joint Shantou International Eye Center
Nathan Congdon
7/F, Block B, Department of Ophthalmology and Visual Science,Prince of Wales Hospital, Shatin NT
Email: NCONGDON@CUHK.EDU.HK , Phone: +852 6113 4445
Nathan Congdon
7/F, Block B, Department of Ophthalmology and Visual Science,Prince of Wales Hospital, Shatin NT
Email: NCONGDON@CUHK.EDU.HK , Phone: +852 6113 4445
Randomized, Short-term Trial of Gingko Biloba in the Treatment of Normal Tension and High-Tension Glaucoma
NIL
Yes
2008-05-16
Normal Tension Glaucoma, High Tension Glaucoma
Drug
Gingko Biloba 240mg QD
Eight weeks
Placebo ¡V Calcium tablets
Inclusion Criteria: A. Definite glaucomatous VF (at least three contiguous points in one hemi-field abnormal below the 1% level, two of which are observed on three successive VF tests) and disc damage (CDR >= 0.7 and/or a rim width of <= 0.1 in at least one quadrant, as graded by a glaucoma specialist) in at least one eye. B. For NTG: Average of two highest readings on 12-hour IOP testing off of any ocular hypertensive treatment are <= 18 mmHg C. For pressure-dependent glaucoma: Documented IOP >= 22 mmHg on at least two occasions Exclusion Criteria: a. Any history of dementia or other cognitive abnormality, or evidence on examination or history of non-ocular causes for VF loss. b. Any evidence of disc pallor, retinal abnormality or other finding on ocular examination to suggest an ocular cause other than glaucoma for the VF loss or disc abnormality. c. Need for surgical intervention of any kind, or change in medication within one month of initiating participation in the study.
Randomized
Placebo
Double-blind
Crossover
2008-07-18
60
Unknown
a. Visual field: MD, CPSD, and change in these two parameters before and after treatment over 8 weeks. b. Optic nerve blood flow, and change before and after treatment over 8 weeks. c. Visual function and change before and after treatment d. Effect of treatment type (GBE versus placebo) on the three above parameters e. Effect of glaucoma type (NTG versus pressure-dependent) on changes in VF, visual function and blood flow parameters
f. Change in effect on blood flow, visual function and VF parameters with continued treatment over time with GBE (total of 8 months after cessation of randomized therapy)
2013-05-06
No
NIL
|
|
|
|
|
---|---|---|---|---|
No documents yet. |